1
|
Zhang Y, Bian Z, Chen Y, Jiang E, Chen T, Wang C. Positive association between research competitiveness of Chinese academic hospitals and the scale of their biobanks: A national survey. Clin Transl Sci 2022; 15:2909-2917. [PMID: 36177952 PMCID: PMC9747119 DOI: 10.1111/cts.13408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2022] [Revised: 08/10/2022] [Accepted: 08/16/2022] [Indexed: 01/26/2023] Open
Abstract
Biobanks are important research infrastructure developed rapidly by Chinese hospitals. The objective of this study is to investigate the association between the comprehensive research competitiveness of hospitals and the development of hospital biobanks. In 2018, we conducted a national survey among Chinese biobank managers and directors. An online questionnaire was used to collect data of biobank characteristics. Of the 70 academic hospital biobanks responded to our survey, 49 of their hospitals were listed in the Science and Technology Evaluation Metrics (STEM) and 46 of their hospitals were listed in the Fudan Hospital Rankings, respectively, in 2018. Hospital scores from the STEM and Fudan Hospital Rankings were identified from their official websites. Multivariate linear regression analyses were used to assess the associations of STEM scores and Fudan Hospital Rankings with the scale of biobanks. The overall STEM score, Scientific and Technological Output, and Academic Impact in hospitals with large-scale biobanks were 48.35%, 55.16%, and 58.65% higher than those with small-scale biobanks, respectively. The scale of biobanks was positively associated with STEM score (β = 0.367, p = 0.009), Scientific and Technological Output (β = 0.441, p = 0.001), and Academic Impact (β = 0.304, p = 0.044) after adjustment for potential confounders. For Fudan Hospital Rankings, the comprehensive score and sustainable development ability score were higher in hospitals with large-scale biobanks. Further analyses showed that the scale of the biobanks was positively associated with a higher comprehensive score (β = 0.313, p = 0.037) and a sustainable development ability score (β = 0.463, p < 0.001). The scale of hospital biobanks was positively associated with the research competitiveness of Chinese hospitals.
Collapse
Affiliation(s)
- Yinan Zhang
- Shanghai Jiao Tong University Affiliated Sixth People's HospitalThe Metabolic Disease BiobankShanghaiChina
| | - Zhouliang Bian
- The Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of MedicineShanghaiChina
| | - Yuanyuan Chen
- Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of Digestive System Tumor of Zhejiang ProvinceTaizhou Hospital of Zhejiang ProvinceZhejiangChina,Biological Resource Center, Taizhou Hospital of Zhejiang ProvinceWenzhou Medical UniversityZhejiangChina
| | - Erpeng Jiang
- Shanghai International Medical CenterShanghaiChina
| | - Tianlu Chen
- Center for Translational Medicine and Shanghai Key Laboratory of Diabetes MellitusShanghai Jiao Tong University Affiliated Sixth People's HospitalShanghaiChina
| | - Congrong Wang
- Department of Endocrinology & Metabolism, Shanghai Fourth People's Hospital, School of MedicineTongji UniversityShanghaiChina
| |
Collapse
|
2
|
Matharoo-Ball B, Diop M, Kozlakidis Z. Harmonizing the COVID-19 sample biobanks: Barriers and opportunities for standards, best practices and networks. BIOSAFETY AND HEALTH 2022; 4:280-282. [PMID: 35844964 PMCID: PMC9270233 DOI: 10.1016/j.bsheal.2022.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Revised: 06/27/2022] [Accepted: 06/30/2022] [Indexed: 11/17/2022] Open
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has highlighted the practice of infectious diseases biobanking, as well as existing challenges and opportunities. Thus, the future of infectious diseases biobanking in the post-pandemic era, shall not be an "entry-level version" of its counterpart in non-communicable diseases and large population cohorts, but incorporate the lessons learned. Biobanks constitute a critical research infrastructure supported by harmonized practices through the implementation of international standards, and perceived within the broader scope of healthcare's intersection with research. This perspective paper considers the barriers in biobanking and standardization of practices, as well as the emerging opportunities in the field.
Collapse
Affiliation(s)
| | | | - Zisis Kozlakidis
- International Agency for Research on Cancer, World Health Organization, 69372 Lyon CEDEX 08, France
| |
Collapse
|
3
|
Chróścicka A, Paluch A, Kalaszczyńska I, Szabłowska-Gadomska I. Biobank Personnel - The Key to its Success. Altern Lab Anim 2022; 50:275-281. [PMID: 35862125 DOI: 10.1177/02611929221113976] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Resources from biobanks and biorepositories, such as human samples, are of increasing interest to specialists in various fields. However, whilst biobanks provide a crucial service, their efficient and effective management can prove challenging. When establishing a biobank many factors should be considered, such as the need for appropriate infrastructure, equipment, financial support, and highly specialised and suitably qualified personnel. The number and qualifications of the necessary personnel depend both on the biobank's size and type - i.e. a biobank that is large and diversified in terms of the stored material should be organised differently to a small biorepository. The core of the biobank should be composed of highly trained personnel that closely co-operate with the general and quality control manager. Due to the large amount of data related to the samples, an IT specialist might be needed. In the case of large population biobanks, personnel responsible for patient recruitment, documentation handling, sample collection and distribution to the biobank would be necessary. Furthermore, staff responsible for the infrastructure are also highly important, as they are the first responders to failures that may be critical for the biobank functioning. Depending on the type and size of the biobank/biorepository, some responsibilities and tasks could potentially be combined. Nevertheless, highly trained personnel with clear and precisely defined duties are the key to the proper functioning of a biobank.
Collapse
Affiliation(s)
- Anna Chróścicka
- Department of Histology and Embryology, Center for Biostructure Research, 37803Medical University of Warsaw, Warsaw, Poland.,Laboratory for Cell Research and Application, 37803Medical University of Warsaw, Warsaw, Poland.,BBMRI.pl Consortium
| | - Angelika Paluch
- Laboratory for Cell Research and Application, 37803Medical University of Warsaw, Warsaw, Poland.,BBMRI.pl Consortium
| | - Ilona Kalaszczyńska
- Department of Histology and Embryology, Center for Biostructure Research, 37803Medical University of Warsaw, Warsaw, Poland.,Laboratory for Cell Research and Application, 37803Medical University of Warsaw, Warsaw, Poland
| | - Ilona Szabłowska-Gadomska
- Laboratory for Cell Research and Application, 37803Medical University of Warsaw, Warsaw, Poland.,BBMRI.pl Consortium
| |
Collapse
|
4
|
Zhu Y, Jackson D, Hunter B, Beattie L, Turner L, Hambly BD, Jeremy RW, Malecki C, Robertson EN, Li A, Remedios C, Richmond D, Semsarian C, O'Sullivan JF, Bannon PG, Lal S. Models of cardiovascular surgery biobanking to facilitate translational research and precision medicine. ESC Heart Fail 2021; 9:21-30. [PMID: 34931483 PMCID: PMC8787984 DOI: 10.1002/ehf2.13768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2021] [Revised: 11/07/2021] [Accepted: 12/02/2021] [Indexed: 11/17/2022] Open
Abstract
Biobanking in health care has evolved over the last few decades from simple biological sample repositories to complex and dynamic units with multi‐organizational infrastructure networks and has become an essential tool for modern medical research. Cardiovascular tissue biobanking provides a unique opportunity to utilize cardiac and vascular samples for translational research into heart failure and other related pathologies. Current techniques for diagnosis, classification, and treatment monitoring of cardiac disease relies primarily on interpretation of clinical signs, imaging, and blood biomarkers. Further research at the disease source (i.e. myocardium and blood vessels) has been limited by a relative lack of access to quality human cardiac tissue and the inherent shortcomings of most animal models of heart disease. In this review, we describe a model for cardiovascular tissue biobanking and databasing, and its potential to facilitate basic and translational research. We share techniques to procure endocardial samples from patients with hypertrophic cardiomyopathy, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction, in addition to aortic disease samples. We discuss some of the issues with respect to data collection, privacy, biobank consent, and the governance of tissue biobanking. The development of tissue biobanks as described here has significant scope to improve and facilitate translational research in multi‐omic fields such as genomics, transcriptomics, proteomics, and metabolomics. This research heralds an era of precision medicine, in which patients with cardiovascular pathology can be provided with optimized and personalized medical care for the treatment of their individual phenotype.
Collapse
Affiliation(s)
- YingYan Zhu
- Department of Cardiothoracic Surgery Royal Prince Alfred Hospital Sydney New South Wales Australia
| | - Dan Jackson
- Department of Cardiothoracic Surgery Royal Prince Alfred Hospital Sydney New South Wales Australia
| | - Benjamin Hunter
- Cardiovascular Precision Laboratory The University of Sydney Sydney New South Wales 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney New South Wales Australia
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
| | - Lorna Beattie
- Department of Cardiothoracic Surgery Royal Prince Alfred Hospital Sydney New South Wales Australia
- The Baird Institute for Applied Heart and Lung Surgical Research Sydney New South Wales Australia
| | - Lisa Turner
- Department of Cardiothoracic Surgery Royal Prince Alfred Hospital Sydney New South Wales Australia
- The Baird Institute for Applied Heart and Lung Surgical Research Sydney New South Wales Australia
| | - Brett D. Hambly
- Charles Perkins Centre The University of Sydney Sydney New South Wales Australia
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
| | - Richmond W. Jeremy
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- The Baird Institute for Applied Heart and Lung Surgical Research Sydney New South Wales Australia
- Department of Cardiology Royal Prince Alfred Hospital Sydney New South Wales Australia
| | - Cassandra Malecki
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
| | - Elizabeth N. Robertson
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- Department of Cardiology Royal Prince Alfred Hospital Sydney New South Wales Australia
| | - Amy Li
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- Department of Pharmacy & Biomedical Sciences La Trobe University Melbourne Victoria Australia
| | - Cris Remedios
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
| | - David Richmond
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- Department of Cardiology Royal Prince Alfred Hospital Sydney New South Wales Australia
| | - Christopher Semsarian
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- Department of Cardiology Royal Prince Alfred Hospital Sydney New South Wales Australia
- Agnes Ginges Centre for Molecular Cardiology Centenary Institute Sydney New South Wales Australia
| | - John F. O'Sullivan
- Cardiovascular Precision Laboratory The University of Sydney Sydney New South Wales 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney New South Wales Australia
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- Department of Cardiology Royal Prince Alfred Hospital Sydney New South Wales Australia
- Heart Research Institute The University of Sydney Sydney New South Wales Australia
| | - Paul G. Bannon
- Department of Cardiothoracic Surgery Royal Prince Alfred Hospital Sydney New South Wales Australia
- Charles Perkins Centre The University of Sydney Sydney New South Wales Australia
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- The Baird Institute for Applied Heart and Lung Surgical Research Sydney New South Wales Australia
- RPA Institute of Academic Surgery (IAS) Royal Prince Alfred Hospital and the University of Sydney Sydney New South Wales Australia
| | - Sean Lal
- Cardiovascular Precision Laboratory The University of Sydney Sydney New South Wales 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney New South Wales Australia
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- The Baird Institute for Applied Heart and Lung Surgical Research Sydney New South Wales Australia
- Department of Cardiology Royal Prince Alfred Hospital Sydney New South Wales Australia
| |
Collapse
|
5
|
O'Donoghue S, Dee S, Byrne JA, Watson PH. How Many Health Research Biobanks Are There? Biopreserv Biobank 2021; 20:224-228. [PMID: 34582255 DOI: 10.1089/bio.2021.0063] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Introduction: It is important for many research stakeholders to know how many biobanks exist. There are several potential data sources that might be expected to provide biobank numbers, such as institutions, research funders, and literature databases (e.g., PubMed), but in practice this information is rarely available and is hard to find. However, the maturation of several online health research biobank locators (also known as directories and catalogs) that relate to 12 countries and/or states has now provided some initial data to address the question of how many health research biobanks exist in relation to population size. Methods: We have analyzed four biobank locators: the Biobanking and Biomolecular Resources Research Infrastructure-European Research Infrastructure Consortium directory, the Canadian Tissue Repository Network locator, the Australian New South Wales Australia Health Pathology locator, and the UK Clinical Research Collaboration Tissue Directory. Results: We conclude that across these locators, and in those regions with potential for high research capacity as indicated by comparable gross domestic products, there are 11-30 health research biobanks/million population (2 large biobanks with >1000 samples and a further 9-28 are medium-small biobanks). Conclusion: Many locators were established primarily to increase utilization of biobanks. However, locators may be more useful in tracking the numbers of biobanks and in assisting funders and institutions to monitor research strategy and prevent unnecessary duplication of biobank resources.
Collapse
Affiliation(s)
- Sheila O'Donoghue
- Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer Victoria Center, Victoria, Canada
| | - Simon Dee
- Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer Victoria Center, Victoria, Canada
| | - Jennifer A Byrne
- New South Wales Health Statewide Biobank, New South Wales Health Pathology, Camperdown, Australia.,School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia
| | - Peter Hamilton Watson
- Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer Victoria Center, Victoria, Canada.,Canadian Tissue Repository Network, Vancouver, Canada
| |
Collapse
|
6
|
Beusink M, Broeks A, van Kemenade FJ, Lam KH, Schmidt MK, Rebers S. Barriers and Facilitators for Implementing a National Guideline to Foster the Responsible Use of Residual Biospecimens and Data in Health Research. Biopreserv Biobank 2021; 20:67-74. [PMID: 34582256 DOI: 10.1089/bio.2020.0164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Residual biospecimens that are stored in hospitals' diagnostic specimen archives can be used for scientific research under strict legal and ethical regulations. In the Netherlands, a Code of Conduct governs responsible secondary use of residual biospecimens. However, implementation of this Code seems to be challenging. This study aims to explore the most important factors that facilitate or hinder the implementation of the Code. In addition, it investigates what is needed to further foster the responsible use of residual biospecimens. A mixed-methods design was used. Questionnaires were sent out to pathologists, patient information centers, physicians, researchers, data protection officers (DPOs), members of research ethics committees, and members of the boards of directors of all hospitals in the Netherlands (81 hospitals). To further investigate the barriers and facilitators, interviews were conducted with pathologists, patient information centers, physician-researchers, DPOs, review boards, research coordinators, and quality managers of pathology departments. In total, 246 respondents filled out the questionnaire and 36 interviews were conducted. Major barriers for implementing were a lack of resources (time, money), a lack of attention for responsible use, and a lack of practical knowledge (knowing what to do, where to go with questions). In contrast, the perception that implementing the Code was necessary, either by the respondent or by colleagues, was considered "a driver" for implementation. Practical instruments such as checklists and roadmaps were considered necessary to foster implementation; however, the creation of such instruments was hindered by a lack of clear-cut answers regarding legal aspects. Therefore, more clarity and harmonization on how to interpret both the Code and legislation regarding secondary use were considered necessary.
Collapse
Affiliation(s)
- Miriam Beusink
- Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Annegien Broeks
- Core Facility-Molecular Pathology and Biobanking, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | | | - King H Lam
- Pathology Department, Erasmus MC, Rotterdam, The Netherlands
| | - Marjanka K Schmidt
- Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Susanne Rebers
- Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| |
Collapse
|
7
|
Igumbor JO, Bosire EN, Vicente-Crespo M, Igumbor EU, Olalekan UA, Chirwa TF, Kinyanjui SM, Kyobutungi C, Fonn S. Considerations for an integrated population health databank in Africa: lessons from global best practices. Wellcome Open Res 2021; 6:214. [PMID: 35224211 PMCID: PMC8844538 DOI: 10.12688/wellcomeopenres.17000.1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/12/2021] [Indexed: 12/17/2022] Open
Abstract
Background: The rising digitisation and proliferation of data sources and repositories cannot be ignored. This trend expands opportunities to integrate and share population health data. Such platforms have many benefits, including the potential to efficiently translate information arising from such data to evidence needed to address complex global health challenges. There are pockets of quality data on the continent that may benefit from greater integration. Integration of data sources is however under-explored in Africa. The aim of this article is to identify the requirements and provide practical recommendations for developing a multi-consortia public and population health data-sharing framework for Africa. Methods: We conducted a narrative review of global best practices and policies on data sharing and its optimisation. We searched eight databases for publications and undertook an iterative snowballing search of articles cited in the identified publications. The Leximancer software © enabled content analysis and selection of a sample of the most relevant articles for detailed review. Themes were developed through immersion in the extracts of selected articles using inductive thematic analysis. We also performed interviews with public and population health stakeholders in Africa to gather their experiences, perceptions, and expectations of data sharing. Results: Our findings described global stakeholder experiences on research data sharing. We identified some challenges and measures to harness available resources and incentivise data sharing. We further highlight progress made by the different groups in Africa and identified the infrastructural requirements and considerations when implementing data sharing platforms. Furthermore, the review suggests key reforms required, particularly in the areas of consenting, privacy protection, data ownership, governance, and data access. Conclusions: The findings underscore the critical role of inclusion, social justice, public good, data security, accountability, legislation, reciprocity, and mutual respect in developing a responsive, ethical, durable, and integrated research data sharing ecosystem.
Collapse
Affiliation(s)
- Jude O. Igumbor
- School of Public Health, University of the Witwatersrand, Johannesburg, Gauteng, 2193, South Africa
| | - Edna N. Bosire
- School of Public Health, University of the Witwatersrand, Johannesburg, Gauteng, 2193, South Africa
| | - Marta Vicente-Crespo
- School of Public Health, University of the Witwatersrand, Johannesburg, Gauteng, 2193, South Africa
- African Population and Health Research Centre, Nairobi, Kenya
| | - Ehimario U. Igumbor
- Nigeria Centre for Disease Control, Abuja, Nigeria
- School of Public Health, University of the Western Cape, Cape Town, Western Cape, South Africa
| | - Uthman A. Olalekan
- Warwick-Centre for Applied Health Research and Delivery (WCAHRD), Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK
| | - Tobias F. Chirwa
- School of Public Health, University of the Witwatersrand, Johannesburg, Gauteng, 2193, South Africa
| | | | | | - Sharon Fonn
- School of Public Health, University of the Witwatersrand, Johannesburg, Gauteng, 2193, South Africa
| |
Collapse
|
8
|
The landscape of biobanks in Poland-characteristics of Polish biobanking units at the beginning of BBMRI.pl organization. J Transl Med 2021; 19:267. [PMID: 34158056 PMCID: PMC8218293 DOI: 10.1186/s12967-021-02926-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Accepted: 06/04/2021] [Indexed: 12/01/2022] Open
Abstract
Background Biobanking is an area of scientific activity that is growing in strength and importance. The variety of collections combining biological samples and medical scientific information makes biobanking an indispensable tool in the development of modern medicine. In 2016, Poland, a country with one of the largest populations in Europe, joined the Biobanking and BioMolecular resources Research Infrastructure-European Research Infrastructure Consortium (BBMRI-ERIC) to facilitate access to quality-defined human disease-relevant biological resources. This push led to the development of the Polish Biobanking Network. The purpose of this paper is to present the current state of biobanks in Poland in the context of their location, nature and resources. Methods To obtain information about and overall characteristics of Polish entities dealing with biobanking biological material, the dedicated Information Survey was designed. The survey was prepared in an electronic form and consisted of 53 questions—both open and closed, single and multiple choice—with some questions depending on each other. Sixty-five Polish biobanks/biorepositories participated in the survey. Results Polish biobanks are mostly affiliated with research entities (universities—42% and research institutes—30%). The data collected indicate that a considerable number of Polish biobanks are specialized (33 units), in contrast to population-based biobanks (8 units). These biobanks are mostly focused on collecting samples from oncological (23 biobanks) and rare diseases (12 biobanks). In general, great diversity was found in the material collected. Scientists working in Polish biobanks are very open to scientific cooperation (declared by 60% of units) and sharing their collections with the international scientific environment. In terms of quality issues, most biobanks declared that their quality management system was in the process of implementation (45%) or had already been implemented (23%). Conclusions Although biobanking in Poland is still in its infancy, the results of this study seem promising and may be valuable to the wider biobanking research community. The distribution of biobanks throughout the Polish territory, their connection with scientific and clinical units, and their involvement in research on rare diseases may contribute to an increase in the number of multicenter studies.
Collapse
|
9
|
Trein P, Wagner J. Governing Personalized Health: A Scoping Review. Front Genet 2021; 12:650504. [PMID: 33968134 PMCID: PMC8097042 DOI: 10.3389/fgene.2021.650504] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Accepted: 03/17/2021] [Indexed: 01/03/2023] Open
Abstract
Genetic research is advancing rapidly. One important area for the application of the results from this work is personalized health. These are treatments and preventive interventions tailored to the genetic profile of specific groups or individuals. The inclusion of personalized health in existing health systems is a challenge for policymakers. In this article, we present the results of a thematic scoping review of the literature dealing with governance and policy of personalized health. Our analysis points to four governance challenges that decisionmakers face against the background of personalized health. First, researchers have highlighted the need to further extend and harmonize existing research infrastructures in order to combine different types of genetic data. Second, decisionmakers face the challenge to create trust in personalized health applications, such as genetic tests. Third, scholars have pointed to the importance of the regulation of data production and sharing to avoid discrimination of disadvantaged groups and to facilitate collaboration. Fourth, researchers have discussed the challenge to integrate personalized health into regulatory-, financing-, and service provision structures of existing health systems. Our findings summarize existing research and help to guide further policymaking and research in the field of personalized health governance.
Collapse
Affiliation(s)
- Philipp Trein
- Department of Political Science and International Relations, University of Geneva, Geneva, Switzerland
| | - Joël Wagner
- Department of Actuarial Science, Faculty of Business and Economics (HEC Lausanne), University of Lausanne, Lausanne, Switzerland.,Swiss Finance Institute, University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
10
|
Chen Y, Sang C, Bian Z, Zhang Y, Jiang E, Zhou X, Chen T, Tang H, Wang C. The Scale, Collections, and Biospecimen Distribution of Grade A Tertiary Hospital Biobanks in China: A National Survey. Front Med (Lausanne) 2021; 7:560600. [PMID: 33537321 PMCID: PMC7848138 DOI: 10.3389/fmed.2020.560600] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Accepted: 12/21/2020] [Indexed: 11/13/2022] Open
Abstract
Chinese clinical biobanks were built rapidly in grade A tertiary hospitals. However, the general information of biorepositories in China remained largely unknown. The aim of this study was to investigate the size, collections, biospecimens distribution and other characteristics of Chinese biobanks in grade A tertiary hospitals. In 2018, we launched a national survey among biobank leaders to provide a comprehensive understanding of Chinese grade A tertiary hospital biobanks. A total of 70 biobank managers or directors completed an online questionnaire to collect information about the biorepositories. Nearly 20% of biobanks stored over one million specimens, while almost one-third of biobanks stored 50-200,000 specimens. In general, plasma and serum were the specimens most commonly stored. For the use of collections, biospecimens were most commonly applied by internal clinical departments. Further analyses revealed that the large-scale biobanks were characterized by earlier establishment, more types of specimens in storage and distribution compared with small-scale biobanks. Moreover, specimens in large-scale biobanks were more commonly used for basic research (62.86% vs. 34.29%, P = 0.017) and clinical research (57.14% vs. 28.57%, P = 0.016). Large-scale biobanks also had more opportunities to cooperate with domestic research institutes (34.29% vs. 5.71%, P = 0.003). Our survey revealed diversity in collections, distribution and utilization of biospecimens among Chinese grade A tertiary hospital biobanks. Although the biobanks had relatively large collections, the underutilization of stored biospecimens and lack of sharing could hamper clinical and biological research.
Collapse
Affiliation(s)
- Yuanyuan Chen
- Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.,Translational Medical Center for Stem Cell Therapy & Institute for Regenerative Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
| | - Chao Sang
- Center for Translational Medicine, Shanghai Sixth People's Hospital, Shanghai, China
| | - Zhouliang Bian
- Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yinan Zhang
- The Metabolic Diseases Biobank, Shanghai Key Laboratory of Diabetes, Shanghai Sixth People's Hospital, Shanghai, China
| | - Erpeng Jiang
- Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.,Translational Medical Center for Stem Cell Therapy & Institute for Regenerative Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
| | | | - Tianlu Chen
- Center for Translational Medicine, Shanghai Sixth People's Hospital, Shanghai, China
| | - Hongming Tang
- Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.,Translational Medical Center for Stem Cell Therapy & Institute for Regenerative Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
| | - Congrong Wang
- Department of Endocrinology, Shanghai Fourth People's Hospital Affiliated to Tongji University, Shanghai, China
| |
Collapse
|
11
|
Anisimov SV, Meshkov AN, Glotov AS, Borisova AL, Balanovsky OP, Belyaev VE, Granstrem OK, Grivtsova LY, Efimenko AY, Pokrovskaya MS, Semenenko TA, Sukhorukov VS, Kaprin AD, Drapkina OM. National Association of Biobanks and Biobanking Specialists: New Community for Promoting Biobanking Ideas and Projects in Russia. Biopreserv Biobank 2020; 19:73-82. [PMID: 33058731 DOI: 10.1089/bio.2020.0049] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The research biobanking field is developing rapidly in Russia. Over the course of the last decade, numerous biobanks were created or formed from existing collections of human and environmental biospecimens. The Russian National Association of Biobanks and Biobanking Specialists (NASBIO) was established in December 2018, aiming to: (1) unite professionals and research centers to create and develop a network of biobanks in Russia; (2) provide services and expertise in the field of biobanking; (3) execute various research projects utilizing biobanks' infrastructure; and (4) facilitate integration of Russian biomedical research centers into global research activities. The organizational structure, aims, and plans of this newly formed national association are reviewed in this article. The founders of NASBIO hope that the association will promote further development of biobanks and their networking in Russia, which is critically important for the success of national biomedical, pharmaceutical, and biotechnological research, and can facilitate international biobanking projects on a global scale.
Collapse
Affiliation(s)
| | - Alexey N Meshkov
- National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
| | - Andrey S Glotov
- D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Saint-Petersburg, Russia
| | - Anna L Borisova
- National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
| | - Oleg P Balanovsky
- N.I. Vavilov Institute of General Genetics, Research Centre for Medical Genetics, Biobank of North Eurasia, Moscow, Russia
| | - Vladimir E Belyaev
- Biobank, Institute for Regenerative Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | | | | | - Anastasiya Yu Efimenko
- Institute for Regenerative Medicine, Medical Research and Educational Center, M.V. Lomonosov Moscow State University, Moscow, Russia
| | - Maria S Pokrovskaya
- National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
| | - Tatyana A Semenenko
- N.F. Gamaleya National Research Center for Epidemiology and Microbiology, Moscow, Russia
| | | | | | - Oxana M Drapkina
- National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
| |
Collapse
|
12
|
Lensink MA, Jongsma KR, Boers SN, Noordhoek JJ, Beekman JM, Bredenoord AL. Responsible use of organoids in precision medicine: the need for active participant involvement. Development 2020; 147:147/7/dev177972. [DOI: 10.1242/dev.177972] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
ABSTRACT
Organoids are three-dimensional multicellular structures grown in vitro from stem cells and which recapitulate some organ function. They are derivatives of living tissue that can be stored in biobanks for a multitude of research purposes. Biobank research on organoids derived from patients is highly promising for precision medicine, which aims to target treatment to individual patients. The dominant approach for protecting the interests of biobank participants emphasizes broad consent in combination with privacy protection and ex ante (predictive) ethics review. In this paradigm, participants are positioned as passive donors; however, organoid biobanking for precision medicine purposes raises challenges that we believe cannot be adequately addressed without more ongoing involvement of patient-participants. In this Spotlight, we argue why a shift from passive donation towards more active involvement is particularly crucial for biobank research on organoids aimed at precision medicine, and suggest some approaches appropriate to this context.
Collapse
Affiliation(s)
- Michael A. Lensink
- Department of Medical Humanities, University Medical Center Utrecht, Utrecht University, PO Box 85500, 3508 GA Utrecht, The Netherlands
| | - Karin R. Jongsma
- Department of Medical Humanities, University Medical Center Utrecht, Utrecht University, PO Box 85500, 3508 GA Utrecht, The Netherlands
| | - Sarah N. Boers
- Department of Medical Humanities, University Medical Center Utrecht, Utrecht University, PO Box 85500, 3508 GA Utrecht, The Netherlands
| | - Jacquelien J. Noordhoek
- Dutch Cystic Fibrosis Foundation (NCFS), Dr. A. Schweitzerweg 3A, 3744 MG Baarn, The Netherlands
| | - Jeffrey M. Beekman
- Department of Pediatric Pulmonology, Wilhelmina Children's Hospital, Regenerative Medicine Center, University Medical Center, Internal post KH.01.419.0, P.O. Box 85090, 3508 AB Utrecht, The Netherlands
| | - Annelien L. Bredenoord
- Department of Medical Humanities, University Medical Center Utrecht, Utrecht University, PO Box 85500, 3508 GA Utrecht, The Netherlands
| |
Collapse
|
13
|
Lermen D, Gwinner F, Bartel-Steinbach M, Mueller SC, Habermann JK, Balwir MB, Smits E, Virgolino A, Fiddicke U, Berglund M, Åkesson A, Bergstrom A, Leander K, Horvat M, Snoj Tratnik J, Posada de la Paz M, Castaño Calvo A, Esteban López M, von Briesen H, Zimmermann H, Kolossa-Gehring M. Towards Harmonized Biobanking for Biomonitoring: A Comparison of Human Biomonitoring-Related and Clinical Biorepositories. Biopreserv Biobank 2020; 18:122-135. [PMID: 32281895 PMCID: PMC7185365 DOI: 10.1089/bio.2019.0092] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Human biomonitoring (HBM) depends on high-quality human samples to identify status and trends in exposure and ensure comparability of results. In this context, much effort has been put into the development of standardized processes and quality assurance for sampling and chemical analysis, while effects of sample storage and shipment on sample quality have been less thoroughly addressed. To characterize the currently applied storage and shipment procedures within the consortium of the European Human Biomonitoring Initiative (HBM4EU), which aims at harmonization of HBM in Europe, a requirement analysis based on data from an online survey was conducted. In addition, the online survey was addressed to professionals in clinical biobanking represented by members of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB) to identify the current state-of-the-art in terms of sample storage and shipment. Results of this survey conducted in these two networks were compared to detect processes with potential for optimization and harmonization. In general, many similarities exist in sample storage and shipment procedures applied by ESBB members and HBM4EU partners and many requirements for ensuring sample quality are already met also by HBM4EU partners. Nevertheless, a need for improvement was identified for individual steps in sample storage, shipment, and related data management with potential impact on sample and data quality for HBM purposes. Based on these findings, recommendations for crucial first steps to further strengthen sample quality, and thus foster advancement in HBM on a pan-European level are given.
Collapse
Affiliation(s)
- Dominik Lermen
- Fraunhofer Institute for Biomedical Engineering IBMT, Biomonitoring & Biobanks, Sulzbach, Germany
- European, Middle Eastern & African Society for Biopreservation and Biobanking, Brussels, Belgium
- The European Human-Biomonitoring Initiative HBM4EU
| | - Frederik Gwinner
- Fraunhofer Institute for Biomedical Engineering IBMT, Biomonitoring & Biobanks, Sulzbach, Germany
- The European Human-Biomonitoring Initiative HBM4EU
| | - Martina Bartel-Steinbach
- Fraunhofer Institute for Biomedical Engineering IBMT, Biomonitoring & Biobanks, Sulzbach, Germany
- The European Human-Biomonitoring Initiative HBM4EU
| | - Sabine C. Mueller
- Fraunhofer Institute for Biomedical Engineering IBMT, Biomonitoring & Biobanks, Sulzbach, Germany
- The European Human-Biomonitoring Initiative HBM4EU
| | - Jens K. Habermann
- European, Middle Eastern & African Society for Biopreservation and Biobanking, Brussels, Belgium
- University Clinical Center Schleswig-Holstein, University of Luebeck, Translational Surgical Oncology and Biobanking, Luebeck, Germany
| | - Matharoo-Ball Balwir
- European, Middle Eastern & African Society for Biopreservation and Biobanking, Brussels, Belgium
- Nottingham University Hospital, Translational Research and Nottingham Health Science Biobank (NHSB), Nottingham, United Kingdom
| | - Elke Smits
- European, Middle Eastern & African Society for Biopreservation and Biobanking, Brussels, Belgium
- Antwerp University Hospital, University of Antwerp, Division of Medical Director, Edegem, Belgium
| | - Ana Virgolino
- The European Human-Biomonitoring Initiative HBM4EU
- Faculdade de Medicina, Instituto de Saúde Ambiental, Universidade de Lisboa, Lisboa, Portugal
| | - Ulrike Fiddicke
- The European Human-Biomonitoring Initiative HBM4EU
- German Environment Agency (Umweltbundesamt), Berlin, Germany
| | - Marika Berglund
- The European Human-Biomonitoring Initiative HBM4EU
- Institute of Environmental Medicine, Karolinska Institute, Institute of Environmental Medicine (IMM), Stockholm, Sweden
| | - Agneta Åkesson
- The European Human-Biomonitoring Initiative HBM4EU
- Institute of Environmental Medicine, Karolinska Institute, Institute of Environmental Medicine (IMM), Stockholm, Sweden
| | - Anna Bergstrom
- The European Human-Biomonitoring Initiative HBM4EU
- Institute of Environmental Medicine, Karolinska Institute, Institute of Environmental Medicine (IMM), Stockholm, Sweden
| | - Karin Leander
- The European Human-Biomonitoring Initiative HBM4EU
- Institute of Environmental Medicine, Karolinska Institute, Institute of Environmental Medicine (IMM), Stockholm, Sweden
| | - Milena Horvat
- The European Human-Biomonitoring Initiative HBM4EU
- Jožef Stefan Institute, Department of Environmental Sciences, Ljubljana, Slovenia
| | - Janja Snoj Tratnik
- The European Human-Biomonitoring Initiative HBM4EU
- Jožef Stefan Institute, Department of Environmental Sciences, Ljubljana, Slovenia
| | - Manuel Posada de la Paz
- The European Human-Biomonitoring Initiative HBM4EU
- Institute of Rare Diseases Research, CIBERER, EuroBiobanK, Instituto de Salud Carlos III, Madrid, Spain
| | - Argelia Castaño Calvo
- The European Human-Biomonitoring Initiative HBM4EU
- Centro Nacional de Sanidad Ambiental CNSA, Instituto de Salud Carlos III, Majadahonda, Spain
| | - Marta Esteban López
- The European Human-Biomonitoring Initiative HBM4EU
- Centro Nacional de Sanidad Ambiental CNSA, Instituto de Salud Carlos III, Majadahonda, Spain
| | - Hagen von Briesen
- Fraunhofer Institute for Biomedical Engineering IBMT, Biomonitoring & Biobanks, Sulzbach, Germany
- The European Human-Biomonitoring Initiative HBM4EU
| | - Heiko Zimmermann
- Fraunhofer Institute for Biomedical Engineering IBMT, Biomonitoring & Biobanks, Sulzbach, Germany
- The European Human-Biomonitoring Initiative HBM4EU
| | - Marike Kolossa-Gehring
- The European Human-Biomonitoring Initiative HBM4EU
- German Environment Agency (Umweltbundesamt), Berlin, Germany
| |
Collapse
|
14
|
Coppola L, Cianflone A, Grimaldi AM, Incoronato M, Bevilacqua P, Messina F, Baselice S, Soricelli A, Mirabelli P, Salvatore M. Biobanking in health care: evolution and future directions. J Transl Med 2019; 17:172. [PMID: 31118074 PMCID: PMC6532145 DOI: 10.1186/s12967-019-1922-3] [Citation(s) in RCA: 171] [Impact Index Per Article: 34.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Accepted: 05/15/2019] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND The aim of the present review is to discuss how the promising field of biobanking can support health care research strategies. As the concept has evolved over time, biobanks have grown from simple biological sample repositories to complex and dynamic units belonging to large infrastructure networks, such as the Pan-European Biobanking and Biomolecular Resources Research Infrastructure (BBMRI). Biobanks were established to support scientific knowledge. Different professional figures with varied expertise collaborate to obtain and collect biological and clinical data from human subjects. At same time biobanks preserve the human and legal rights of each person that offers biomaterial for research. METHODS A literature review was conducted in April 2019 from the online database PubMed, accessed through the Bibliosan platform. Four primary topics related to biobanking will be discussed: (i) evolution, (ii) bioethical issues, (iii) organization, and (iv) imaging. RESULTS Most biobanks were founded as local units to support specific research projects, so they evolved in a decentralized manner. The consequence is an urgent needing for procedure harmonization regarding sample collection, processing, and storage. Considering the involvement of biomaterials obtained from human beings, different ethical issues such as the informed consent model, sample ownership, veto rights, and biobank sustainability are debated. In the face of these methodological and ethical challenges, international organizations such as BBMRI play a key role in supporting biobanking activities. Finally, a unique development is the creation of imaging biobanks that support the translation of imaging biomarkers (identified using a radiomic approach) into clinical practice by ensuring standardization of data acquisition and analysis, accredited technical validation, and transparent sharing of biological and clinical data. CONCLUSION Modern biobanks permit large-scale analysis for individuation of specific diseases biomarkers starting from biological or digital material (i.e., bioimages) with well-annotated clinical and biological data. These features are essential for improving personalized medical approaches, where effective biomarker identification is a critical step for disease diagnosis and prognosis.
Collapse
Affiliation(s)
- Luigi Coppola
- IRCCS SDN, Naples Via Emanuele Gianturco, 11, 80143 Naples, Italy
| | | | | | | | - Paolo Bevilacqua
- IRCCS SDN, Naples Via Emanuele Gianturco, 11, 80143 Naples, Italy
| | | | - Simona Baselice
- IRCCS SDN, Naples Via Emanuele Gianturco, 11, 80143 Naples, Italy
- Ospedale Evangelico Betania, Naples, Italy
| | - Andrea Soricelli
- IRCCS SDN, Naples Via Emanuele Gianturco, 11, 80143 Naples, Italy
- Department of Sport Sciences & Healthiness, University of Naples Parthenope, Naples, Italy
| | | | - Marco Salvatore
- IRCCS SDN, Naples Via Emanuele Gianturco, 11, 80143 Naples, Italy
| |
Collapse
|
15
|
Ferdyn K, Gleńska-Olender J, Witoń M, Zagórska K, Kozera Ł, Chróścicka A, Matera-Witkiewicz A. Quality Management System in the BBMRI.pl Consortium: Status Before the Formation of the Polish Biobanking Network. Biopreserv Biobank 2019; 17:401-409. [PMID: 31009233 DOI: 10.1089/bio.2018.0127] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Many types of biomedical research projects depend on high-quality biological material with a data set attached. The Quality Management System (QMS) is focused on operational standards for all organizational activities to ensure that the described quality of each procedure, product, or service is guaranteed. The implementation of the QMS is necessary for the provision of both high quality and repeatability of processes in research laboratories. The current status of implementation of the QMS is determined according to the "Organisation of Polish Biobanking Network" within the project "Biobanking and Biomolecular Resources Research Infrastructure BBMRI-ERIC" supported by the Polish Ministry of Science and Higher Education-decision number DIR/WK/2017/01. According to the above, preliminary audits in six Polish institutions were conducted and reports with recommendations concerning the implementation and improvement of the QMS in Polish biobanks were prepared. During all audits, 13 QMS main areas were analyzed. All audited units belong to the BBMRI.pl consortium, which is responsible for the creation of the Polish Biobanking Network within the BBMRI-ERIC structure. Among all 13 analyzed areas, 27 deviations were identified. Eleven of them were implemented in all audited biobanks but defined as the areas for improvement, 16 of them were not implemented correctly or not implemented at all, respectively (areas underlined to corrective procedures).
Collapse
Affiliation(s)
- Katarzyna Ferdyn
- Screening Laboratory of Biological Activity Test and Collection of Biological Material, Faculty of Pharmacy with Division of Laboratory Diagnostics, Wroclaw Medical University, Wroclaw, Poland.,BBMRI.pl Consortium, PORT, Wroclaw, Poland
| | - Joanna Gleńska-Olender
- Screening Laboratory of Biological Activity Test and Collection of Biological Material, Faculty of Pharmacy with Division of Laboratory Diagnostics, Wroclaw Medical University, Wroclaw, Poland.,BBMRI.pl Consortium, PORT, Wroclaw, Poland
| | - Małgorzata Witoń
- Screening Laboratory of Biological Activity Test and Collection of Biological Material, Faculty of Pharmacy with Division of Laboratory Diagnostics, Wroclaw Medical University, Wroclaw, Poland.,BBMRI.pl Consortium, PORT, Wroclaw, Poland
| | - Karolina Zagórska
- Screening Laboratory of Biological Activity Test and Collection of Biological Material, Faculty of Pharmacy with Division of Laboratory Diagnostics, Wroclaw Medical University, Wroclaw, Poland.,BBMRI.pl Consortium, PORT, Wroclaw, Poland
| | - Łukasz Kozera
- BBMRI.pl Consortium, PORT, Wroclaw, Poland.,PORT, Wroclaw, Poland
| | - Anna Chróścicka
- BBMRI.pl Consortium, PORT, Wroclaw, Poland.,Department of Histology and Embryology, Center for Biostructure Research, Center for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland.,Laboratory for Cell Research and Application, Center for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland
| | - Agnieszka Matera-Witkiewicz
- Screening Laboratory of Biological Activity Test and Collection of Biological Material, Faculty of Pharmacy with Division of Laboratory Diagnostics, Wroclaw Medical University, Wroclaw, Poland.,BBMRI.pl Consortium, PORT, Wroclaw, Poland
| |
Collapse
|
16
|
Müller A, Hovanec J, Josephs B, Wiethege T, Brüning T, Behrens T. A Two-Level Biobank Data Protection Concept for Project-Driven Human Sample Collections. Biopreserv Biobank 2019; 17:312-318. [PMID: 30882231 DOI: 10.1089/bio.2018.0112] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Legal and ethical demands for more transparent and strict data protection measures to enhance research participant privacy have grown with an increasing number of human biobanks providing biomaterial collections long term for unspecified future research questions. The design of a data protection scheme that minimizes the risk of donor reidentification and promotes biomaterial and data use in research is a big challenge to all kinds of human biobanks. Yet, there is a lack of publications which address this basic building block of a biobank. In this study, we present the data protection concept of our project driven, stand-alone biobank, focusing on meeting two biomaterial and data management areas simultaneously: operation of primary research projects involved in sample collection and long-term provision of biomaterial for future research purposes. The concept is based on national and international laws and ethical demands. Since the presented measures are transparent and basic, they should encourage biobanks in defining their own data protection concept and be easily transferable to different legal requirements.
Collapse
Affiliation(s)
- Antje Müller
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany
| | - Jan Hovanec
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany
| | - Berthold Josephs
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany
| | - Thorsten Wiethege
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany
| | - Thomas Brüning
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany
| | - Thomas Behrens
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany
| |
Collapse
|
17
|
Hakimi M, Wortmann M, Böckler D, Schirmacher P, Herpel E, Peters AS. Vascular Biomaterial Banking in Academia. Eur Surg Res 2019; 60:13-23. [PMID: 30726831 DOI: 10.1159/000495525] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2018] [Accepted: 11/14/2018] [Indexed: 11/19/2022]
Abstract
BACKGROUND/PURPOSE To establish a high-quality vascular biomaterial bank to serve vascular research teams and act as a basis for translational medicine. The aim was to collect and store material so that investigation into the pathogenesis of vascular disease would be possible employing methods based on histopathology and/or molecular biology. METHODS The Vascular Biomaterialbank Heidelberg (VBBH) evolved as part of an established, partly accredited biobank complex at the University of Heidelberg (BioMaterialBank Heidelberg - BMBH). The BMBH provided infrastructure regarding legal and quality issues as well as safety, protocols for specimen collection, data management, and publication of results. Protocols were modified where necessary to accommodate specific needs of vascular tissue research. Correct identification of vascular biomaterial is controlled by certified vascular surgeons and pathologists at biobank entry and exit. Pseudonymized clinical data are attached to every specimen. RESULTS The VBBH provides standardized operating procedures (SOP) regulating the request, processing, and delivery of material to researchers, as well as project tracking. Tissue samples for a research project are requested by filling out an online application form. Within 3-5 working days, a scientific board, including a member of the VBBH and a member of the BMBH, decide upon acceptance or rejection of the research project. Criteria determining acceptance include whether enough samples are available for the particular investigation and whether planned methods are judged adequate to successfully complete the research project. Through tracking of all ongoing studies involving specimens from the VBBH, methods for tissue conservation are continually being optimized. The VBBH platform has supported numerous high-ranking publications involving diverse medical departments and reflects a gain in translational medicine. CONCLUSIONS SOPs and controls by certified specialists ensure the high quality of specimens obtained through the VBBH. Research performed by vascular surgeons can be facilitated by using the VBBH.
Collapse
Affiliation(s)
- Maani Hakimi
- Department of Vascular and Endovascular Surgery, University of Heidelberg, Heidelberg, Germany.,Vaskuläre Biomaterialbank, Vascular Biomaterialbank Heidelberg (VBBH), University of Heidelberg, Heidelberg, Germany
| | - Markus Wortmann
- Department of Vascular and Endovascular Surgery, University of Heidelberg, Heidelberg, Germany.,Vaskuläre Biomaterialbank, Vascular Biomaterialbank Heidelberg (VBBH), University of Heidelberg, Heidelberg, Germany
| | - Dittmar Böckler
- Department of Vascular and Endovascular Surgery, University of Heidelberg, Heidelberg, Germany
| | - Peter Schirmacher
- Institute of Pathology, University of Heidelberg, Heidelberg, Germany.,National Cancer Institute, Tissue Bank, Heidelberg, Germany
| | - Esther Herpel
- Institute of Pathology, University of Heidelberg, Heidelberg, Germany.,National Cancer Institute, Tissue Bank, Heidelberg, Germany
| | - Andreas S Peters
- Department of Vascular and Endovascular Surgery, University of Heidelberg, Heidelberg, Germany, .,Vaskuläre Biomaterialbank, Vascular Biomaterialbank Heidelberg (VBBH), University of Heidelberg, Heidelberg, Germany,
| |
Collapse
|
18
|
Zhao Y, Feng G, Feng L. Effects of pre-analytical storage time, temperature, and freeze-thaw times on coagulation factors activities in citrate-anticoagulated plasma. ANNALS OF TRANSLATIONAL MEDICINE 2019; 6:456. [PMID: 30603644 DOI: 10.21037/atm.2018.11.24] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Background Coagulation factor assays are very important for diagnosing, treating, and monitoring inherited and acquired factor deficiencies. Appropriate pre-analytical storage conditions of citrate-anticoagulated plasma are essential for detection of coagulation factor activity. We aimed to investigate the effects of storage temperature and time on coagulation factor (F) II, FV, FVII, FX, FXI, and FXII activity up to 24 h and the effects of freeze-thaw times at -80 °C on factor activity. Methods Twenty-two blood samples were analyzed after storage for 0 (baseline), 2, 4, 6, 8, 12, and 24 h at 25 and 4 °C. Mean percent changes, numbers of samples with >10% changes, percent change trend plots, and difference plots were evaluated to determine clinically relevant differences. Results The acceptable storage times for FII coagulation activity (FII:C), FV:C, FVII:C, FX:C, FXI:C, and FXII:C were 24, 8, 8, 24, 12, and 12 h at 4 °C and 24, 4, 8, 8, 12, and 12 h at 25 °C, respectively. The acceptable freeze-thaw times for FII:C, FV:C, FVII:C, FX:C, FXI:C, and FXII:C were 2, 2, 3, 3, 2, and 1, respectively. Conclusions When factor activity cannot be determined within these acceptable timeframes, we recommend that plasma samples should be frozen and thawed at appropriate times for analysis.
Collapse
Affiliation(s)
- Ying Zhao
- Department of Clinical Laboratory, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| | - Guofang Feng
- Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
| | - Limin Feng
- Department of Clinical Laboratory, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| |
Collapse
|
19
|
Paskal W, Paskal AM, Dębski T, Gryziak M, Jaworowski J. Aspects of Modern Biobank Activity - Comprehensive Review. Pathol Oncol Res 2018; 24:771-785. [PMID: 29728978 PMCID: PMC6132819 DOI: 10.1007/s12253-018-0418-4] [Citation(s) in RCA: 72] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2017] [Accepted: 04/27/2018] [Indexed: 12/13/2022]
Abstract
Biobanks play an increasing role in contemporary research projects. These units meet all requirements to regard them as a one of the most innovative and up-to-date in the field of biomedical research. They enable conducting wide-scale research by the professional collection of biological specimens and correlated clinical data. Pathology units may be perceived roots of biobanking. The review aims at describing the concept of biobanks, their model of function and scientific potential. It comprises the division of biobanks, sample preservation methods and IT solutions as well as guidelines and recommendations for management of a vast number of biological samples and clinical data. Therefore, appropriate standard operating procedures and protocols are outlined. Constant individualization of diagnostic process and treatment procedures creates the niche for translational units. Thus, the role of biobanks in personalized medicine was also specified. The exceptionality of biobanks poses some new ethical-legal issues which have various solutions, in each legal system, amongst the world. Finally, distribution and activity of European biobanks are mentioned.
Collapse
Affiliation(s)
- Wiktor Paskal
- The Department of Histology and Embryology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, ul. Banacha 1B, 02-097, Warsaw, Poland.
- Plastic Surgery Department, Centre of Postgraduate Medical Education, Warsaw, Poland.
- The Department of Applied Pharmacy, Medical University of Warsaw, Warsaw, Poland.
| | - Adriana M Paskal
- The Department of Histology and Embryology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, ul. Banacha 1B, 02-097, Warsaw, Poland
| | - Tomasz Dębski
- Plastic Surgery Department, Centre of Postgraduate Medical Education, Warsaw, Poland
| | - Maciej Gryziak
- The Department of Applied Pharmacy, Medical University of Warsaw, Warsaw, Poland
- Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland
| | - Janusz Jaworowski
- The Department of Applied Pharmacy, Medical University of Warsaw, Warsaw, Poland
| |
Collapse
|
20
|
Effects of preanalytical frozen storage time and temperature on screening coagulation tests and factors VIII and IX activity. Sci Rep 2017; 7:12179. [PMID: 28939816 PMCID: PMC5610264 DOI: 10.1038/s41598-017-11777-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Accepted: 08/30/2017] [Indexed: 01/05/2023] Open
Abstract
Preanalytical quality control of blood samples is critical for tests of coagulation function and coagulation factor activity. Preanalytical storage time and temperature are the main variables. We investigated the effects of preanalytical frozen storage time and temperature on activated partial thromboplastin time (APTT), fibrinogen (Fbg), prothrombin time (PT)/international normalized ratio (INR), thrombin time (TT), factor VIII activity (FVIII:C), and factor IX activity (FIX:C) in frozen plasma. Samples (n = 144) were randomly and equally divided into four groups (storage at −80 °C or −20 °C) and analysed by CS5100 or CA7000 coagulation analysers. Baseline values and results after storage for 15 days, 1 month, 3 months, 6 months, and 1 year were measured after thawing. Mean percent changes and scatter plots were used to determine clinically relevant differences. The stabilities of coagulation tests and coagulation factor activities measured by the CS5100 system were consistent with those measured by the CA7000 system. At −80 °C, assessment samples of PT/INR, Fbg, and TT can be safely stored for 1 year, APTT for 6 months, and FVIII:C and FIX:C for 1 month. At −20 °C, samples of Fbg and TT can be stored for 1 year, PT/INR and FIX:C for 1 month, and APTT and FVIII:C for 15 days.
Collapse
|
21
|
Morrison M, Bell J, George C, Harmon S, Munsie M, Kaye J. The European General Data Protection Regulation: challenges and considerations for iPSC researchers and biobanks. Regen Med 2017; 12:693-703. [PMID: 28976812 PMCID: PMC5857917 DOI: 10.2217/rme-2017-0068] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Accepted: 07/26/2017] [Indexed: 02/08/2023] Open
Abstract
Increasingly, human induced pluripotent stem cells (iPSC) and their associated genetic and clinical information are being used in a wide range of applications, with large biobanks being established to support and increase their scientific use. The new European General Data Protection Regulations, which comes into effect in 2018, will have implications for biobanks that generate, store and allow research access to iPSC. This paper describes some of the challenges that iPSC biobanks face and suggests some points for the development of appropriate governance structures to address these new requirements. These suggestions also have implications for iPSC research in general.
Collapse
Affiliation(s)
- Michael Morrison
- Nuffield Department of Population Health, HeLEX – Center for Health, Law & Emerging Technologies, University of Oxford, Ewert House, Ewert Place, Banbury Road, Oxford OX2 7DD, UK
| | - Jessica Bell
- Nuffield Department of Population Health, HeLEX – Center for Health, Law & Emerging Technologies, University of Oxford, Ewert House, Ewert Place, Banbury Road, Oxford OX2 7DD, UK
- Melbourne Law School, University of Melbourne, Parkville, VIC 3010, Australia
| | - Carol George
- School of Law, Kenyon Mason Institute for Medicine, Life Sciences & Law, University of Edinburgh, Old College, South Bridge, Edinburgh EH8 9YL, UK
| | - Shawn Harmon
- School of Law, Kenyon Mason Institute for Medicine, Life Sciences & Law, University of Edinburgh, Old College, South Bridge, Edinburgh EH8 9YL, UK
| | - Megan Munsie
- Department of Anatomy & Neuroscience, Stem Cells Center for Stem Cell Systems, University of Melbourne, Parkville, VIC 3010, Australia
| | - Jane Kaye
- Nuffield Department of Population Health, HeLEX – Center for Health, Law & Emerging Technologies, University of Oxford, Ewert House, Ewert Place, Banbury Road, Oxford OX2 7DD, UK
- Melbourne Law School, University of Melbourne, Parkville, VIC 3010, Australia
| |
Collapse
|
22
|
Larsson A. The Need for Research Infrastructures: A Narrative Review of Large-Scale Research Infrastructures in Biobanking. Biopreserv Biobank 2017; 15:375-383. [PMID: 28253021 DOI: 10.1089/bio.2016.0103] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Distributed Research Infrastructures are gaining political traction in Europe to facilitate scientific research. This development has gained particular momentum in the area of biobanking where cross-national attempts have been made toward harmonizing the biobanking standards across the European Union through the establishment of the organization BBMRI (BioBanking and Biomolecular Resources Research Infrastructure). BBMRI exists as separate national nodes across several European countries, although Sweden took on a pioneering role in its early stages. Thus, the Swedish node, BBMRI.se, was set up in 2009. PURPOSE To document publications addressing the current debate on large-scale distributed medical and/or biobank Research Infrastructures and identify the most pressing issues discussed by these articles through a narrative review. METHODS The Web of Science (WOS) and PubMed databases were searched to find prior studies of large-scale medical Research Infrastructures, with no limits set with regard to study design and/or time period. All identified articles published up until March 2016 were included in the initial review. RESULTS A total of 145 articles were retrieved from WOS and PubMed, though merely 17 ultimately made it past the final exclusion criteria. About two-thirds of the articles listed a first author affiliated to a European country. The articles most commonly discussed the need for developing and expanding the use of "infrastructures." PRACTICAL IMPLICATIONS The future of scientific research will call for a deeper and more widespread multidisciplinary collaboration. This will emphasize the need of research seeking to optimize the preconditions of securing sustainable scientific collaboration. Future investigators will thus need to understand the components and mechanisms of Research Infrastructures in addition to acquiring knowledge of how to build, manage, brand, and promote them as well.
Collapse
Affiliation(s)
- Anthony Larsson
- Department of Learning, Informatics, Management, and Ethics (LIME), Karolinska Institutet , Stockholm, Sweden
| |
Collapse
|
23
|
Li H, Ni M, Wang P, Wang X. A Survey of the Current Situation of Clinical Biobanks in China. Biopreserv Biobank 2017; 15:248-252. [PMID: 28080144 DOI: 10.1089/bio.2016.0095] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
The development of biomedical research urgently needs the support of a large number of high-quality clinical biospecimens. Therefore, human biobanks at different levels have been established successively in China and other countries at a significantly increasing pace in recent years. To better understand the general current state of clinical biobanks in China, we surveyed 42 clinical biobanks based in hospitals and collected information involving their management systems, sharing mechanisms, quality control systems, and informational management systems using closed questionnaire methods. Based on our current information, there has not been such a large-scale survey in China. An understanding of the status and challenges current clinical biobanks face will provide valuable insights for the construction and sustainable development of higher quality clinical biobanks.
Collapse
Affiliation(s)
- Haiyan Li
- 1 School of Health Management and Education, Capital Medical University , Beijing, China .,2 Department of Science and Technology, Capital Medical University , Beijing, China .,3 Beijing Biobank of Clinical Resources , Beijing, China
| | - Mingyu Ni
- 2 Department of Science and Technology, Capital Medical University , Beijing, China .,3 Beijing Biobank of Clinical Resources , Beijing, China
| | - Peng Wang
- 3 Beijing Biobank of Clinical Resources , Beijing, China .,4 Beijing Institute for Brain Disorders , Beijing, China
| | - Xiaomin Wang
- 1 School of Health Management and Education, Capital Medical University , Beijing, China .,3 Beijing Biobank of Clinical Resources , Beijing, China .,4 Beijing Institute for Brain Disorders , Beijing, China
| |
Collapse
|
24
|
Capocasa M, Anagnostou P, D’Abramo F, Matteucci G, Dominici V, Destro Bisol G, Rufo F. Samples and data accessibility in research biobanks: an explorative survey. PeerJ 2016; 4:e1613. [PMID: 26966643 PMCID: PMC4782685 DOI: 10.7717/peerj.1613] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Accepted: 12/30/2015] [Indexed: 12/23/2022] Open
Abstract
Biobanks, which contain human biological samples and/or data, provide a crucial contribution to the progress of biomedical research. However, the effective and efficient use of biobank resources depends on their accessibility. In fact, making bio-resources promptly accessible to everybody may increase the benefits for society. Furthermore, optimizing their use and ensuring their quality will promote scientific creativity and, in general, contribute to the progress of bio-medical research. Although this has become a rather common belief, several laboratories are still secretive and continue to withhold samples and data. In this study, we conducted a questionnaire-based survey in order to investigate sample and data accessibility in research biobanks operating all over the world. The survey involved a total of 46 biobanks. Most of them gave permission to access their samples (95.7%) and data (85.4%), but free and unconditioned accessibility seemed not to be common practice. The analysis of the guidelines regarding the accessibility to resources of the biobanks that responded to the survey highlights three issues: (i) the request for applicants to explain what they would like to do with the resources requested; (ii) the role of funding, public or private, in the establishment of fruitful collaborations between biobanks and research labs; (iii) the request of co-authorship in order to give access to their data. These results suggest that economic and academic aspects are involved in determining the extent of sample and data sharing stored in biobanks. As a second step of this study, we investigated the reasons behind the high diversity of requirements to access biobank resources. The analysis of informative answers suggested that the different modalities of resource accessibility seem to be largely influenced by both social context and legislation of the countries where the biobanks operate.
Collapse
Affiliation(s)
| | - Paolo Anagnostou
- Istituto Italiano di Antropologia, Rome, Italy
- Department of Environmental Biology, Sapienza University of Rome, Rome, Italy
| | | | | | - Valentina Dominici
- Istituto Italiano di Antropologia, Rome, Italy
- Department of Environmental Biology, Sapienza University of Rome, Rome, Italy
| | - Giovanni Destro Bisol
- Istituto Italiano di Antropologia, Rome, Italy
- Department of Environmental Biology, Sapienza University of Rome, Rome, Italy
| | - Fabrizio Rufo
- Istituto Italiano di Antropologia, Rome, Italy
- Department of Environmental Biology, Sapienza University of Rome, Rome, Italy
| |
Collapse
|
25
|
A critical analysis of cancer biobank practices in relation to biospecimen quality. Biophys Rev 2015; 7:369-378. [PMID: 28510101 DOI: 10.1007/s12551-015-0178-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2015] [Accepted: 09/17/2015] [Indexed: 12/26/2022] Open
Abstract
There are concerns that a substantial proportion of published research data is not reproducible, which may partially explain the frequent failure to translate pre-clinical results to clinical care. High-quality cancer biospecimens are needed for robust, reproducible research findings, with most researchers obtaining these specimens from cancer biobanks or tumour banks. This review provides an overview of the types of quality control (QC) activities conducted within cancer biobanks that pertain to biospecimen quality and of biospecimen quality reporting tools, including SPREC and BRISQ. We examine how QC assay results and other biospecimen data are communicated from biobanks to researchers, and whether these activities lead to improved biospecimen quality reporting within the literature and/or to improved research outcomes. We also discuss operational factors that limit QC activities within biobanks and evidence gaps requiring further research. In summary, whereas the provision of quality biospecimens is a common aim of cancer biobanks, QC activities remain underreported and are rarely discussed in the literature, compared with other aspects of biobank operations. Further research is required to determine how biobanks can most efficiently optimise biospecimen quality, and how communication between biobanks and researchers can be improved.
Collapse
|
26
|
Abstract
This article raises the concern that biobanks are failing to realize the expected research and health service outcomes. Rather than biobanking, we have been engaging in ‘biohoarding’, where building a quantifiable collection of tissue samples is the primary basis of the bio-resource. The root cause of ‘biohoarding’ is an ideological and motivational confusion as to the purpose for collecting the tissue in the first place. We have lost sight of the knowledge gain that biobanks should generate. The obligation to prevent ‘biohoarding’ lies not with researchers, funders or managers but with policy makers.
Collapse
Affiliation(s)
- Daniel Catchpoole
- Associate Professor, The Tumour Bank, The Children’s Cancer Research Unit, The Kids Research Institute, Westmead, NSW, Australia
| |
Collapse
|
27
|
How to optimize the use of biobanks from population-based cohorts in aging research. Biogerontology 2015; 17:221-7. [DOI: 10.1007/s10522-015-9586-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2015] [Accepted: 06/13/2015] [Indexed: 12/20/2022]
|
28
|
Vora T, Thacker N. Impacts of a biobank: Bridging the gap in translational cancer medicine. Indian J Med Paediatr Oncol 2015; 36:17-23. [PMID: 25810570 PMCID: PMC4363845 DOI: 10.4103/0971-5851.151773] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
The prevalence of people affected by cancer has been steadily increasing. More and more people are being offered the chance of increased longevity. This has been possible due to advances not only in medicines and techniques but also because of the gain in understanding of cancer biology through Translational Cancer Medicine. A significant step towards obtaining this success was the establishment of successful biobanking practise. In this review we discuss about the importance of a Biobank and the various impacts that a biobank can have not only in the field of cancer but also on many other aspects. Later we discuss a method of quantitative evaluation of these impacts of a biobank.
Collapse
Affiliation(s)
- Tushar Vora
- Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India
| | - Nirav Thacker
- Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India
| |
Collapse
|
29
|
Watson PH. Biobank classification: communicating biorepository diversity. Biopreserv Biobank 2015; 12:163-4. [PMID: 24955732 DOI: 10.1089/bio.2014.1231] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Roessler BJ, Steneck NH, Connally L. The MICHR Genomic DNA BioLibrary: An Empirical Study of the Ethics of Biorepository Development. J Empir Res Hum Res Ethics 2015; 10:37-48. [PMID: 25742665 DOI: 10.1177/1556264614564975] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
In this article, we report on an effort to study the development and usefulness of a large, broad-use, opt-in biorepository for genomic research, focusing on three ethical issues: providing appropriate understanding, recruiting in ways that do not comprise autonomous decisions, and assessing costs versus benefits. We conclude the following: (a) Understanding can be improved by separating the task of informing subjects from documenting informed consent (Common Rule) and permission to use personal health information and samples for research (Health Insurance Portability and Accountability Act [HIPAA]); however, regulations might have to be changed to accommodate this approach. (b) Changing recruiting methods increases efficiency but can interfere with subject autonomy. (c) Finally, we propose a framework for the objective evaluation of the utility of biorepositories and suggest that more attention needs to be paid to use and sustainability.
Collapse
Affiliation(s)
- Blake J Roessler
- Michigan Institute for Clinical and Health Research (MICHR), University of Michigan Medical School, Ann Arbor, Michigan, USA Division of Rheumatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
| | - Nicholas H Steneck
- Michigan Institute for Clinical and Health Research (MICHR), University of Michigan Medical School, Ann Arbor, Michigan, USA Department of History, College of Literature, Science and the Arts, University of Michigan, Ann Arbor, Michigan, USA
| | - Lisa Connally
- Michigan Institute for Clinical and Health Research (MICHR), University of Michigan Medical School, Ann Arbor, Michigan, USA
| |
Collapse
|
31
|
Dove ES. Biobanks, Data Sharing, and the Drive for a Global Privacy Governance Framework. THE JOURNAL OF LAW, MEDICINE & ETHICS : A JOURNAL OF THE AMERICAN SOCIETY OF LAW, MEDICINE & ETHICS 2015; 43:675-689. [PMID: 26711409 DOI: 10.1111/jlme.12311] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Biobanks are a key emerging biomedical research infrastructure. They manifest the turn towards greater global sharing of genomic and health-related data, which is considered by many to be an ethical and scientific imperative. Our collective interests lie in improving the health and welfare of individuals, communities, and populations; improving health and welfare requires access to, and use of, widely dispersed quality data. But sharing these individual and familial data requires in turn that due thought be given to the ethical and legal interests at stake. Most critically, data sharing must occur in an environment whereby privacy interests are safeguarded throughout the lifecycle of biobank initiatives, and regardless of the locations where the data are stored, to which they are sent, and where they are ultimately processed. In this article, I outline the complex dimensions of data privacy regulation that challenge data sharing within the biobanking context. I discuss how harmonization may be a remedy for the gaps and marked differences of approach in data privacy regulation. Finally, I encourage the development of foundational responsible data sharing principles set within an overarching governance framework that provides assurance that reasonable expectations of privacy will be met.
Collapse
Affiliation(s)
- Edward S Dove
- Ph.D. candidate in the School of Law at the University of Edinburgh. Previously, he was an Academic Associate at the Centre of Genomics and Policy at McGill University in Montreal. He received his LL.M. degree from Columbia University
| |
Collapse
|
32
|
|
33
|
Braun L, Lesperance M, Mes-Massons AM, Tsao MS, Watson PH. Individual investigator profiles of biospecimen use in cancer research. Biopreserv Biobank 2014; 12:192-8. [PMID: 24918606 DOI: 10.1089/bio.2013.0092] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Establishing targets for case accrual is an important component of a strategic plan for a biobank. We have previously assessed overall patterns of biospecimen use in cancer research publications in selected journals. Here we extend this analysis to consider patterns of biospecimen use in relation to cancer research programs developed by individual investigators. METHODS We selected three individual cancer research investigators whose independent research programs began circa 1986, have been characterized by extensive use of human tumor biospecimens, and have primarily involved translational research in the areas of breast, lung, and ovarian cancer. We analyzed biospecimen and data usage in their career publications categorized by numbers, type, and format, and accompanying annotating data in terms of conformance with BRISQ reporting and ethics related criteria. RESULTS Biospecimens were used in 313/474 (66%) of publications analyzed. The average number of biospecimens used by these research programs increased six-fold from less than 1000 in 2001-2003 to greater than 6000 in 2010-2012, and the average cohort sizes per article also increased from approximately 50 to 200 cases per study over the same period in most biospecimen categories (p<0.05). The relative proportions of different formats of biospecimens used has varied significantly and continues to change with the emergence of digital biospecimen derived data. In these three translational research programs, BRISQ elements relating to 'Biobank' categories were significantly less well reported for biospecimens used in publications than data corresponding to 'Clinical chart' categories (p<0001). CONCLUSIONS This study shows that overall use of biospecimens in cancer research has increased significantly and that dynamic variation in the relative use of different biospecimen formats has also occurred. This study also confirms our previous findings on patterns of biospecimen use and also those concerning incomplete reporting of relevant data elements that has not improved in the past decade.
Collapse
Affiliation(s)
- Lauren Braun
- 1 Tumour Tissue Repository, Trev and Joyce Deeley Research Centre, BC Cancer Agency , Victoria, British Columbia, Canada
| | | | | | | | | |
Collapse
|
34
|
Affiliation(s)
- Ozren Polasek
- Ozren Polasek, Centre for Global Health, Medical School, University of Split, Split, Croatia,
| |
Collapse
|
35
|
Biobanking 3.0: evidence based and customer focused biobanking. Clin Biochem 2014; 47:300-8. [PMID: 24406300 DOI: 10.1016/j.clinbiochem.2013.12.018] [Citation(s) in RCA: 81] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2013] [Revised: 12/08/2013] [Accepted: 12/13/2013] [Indexed: 01/19/2023]
Abstract
Biobanking is a new and very dynamic field. To achieve long term financial sustainability of biobank infrastructures we propose that a new focus is needed on activities, products and services provided by the biobank that relate to the external stakeholder: biobanking 3.0. Earlier stages of biobanking are biobanking 1.0 (primary focus on the number of biospecimens and data) and biobanking 2.0 (primary focus on the quality of biospecimens and data). Both stages 1.0 and 2.0 are predominantly product oriented areas and have required a mostly internal focus on operational development within the biobank itself. In this paper we will introduce our concept of biobanking 3.0 which capitalizes on the earlier stages but dictates a shift in focus to enhancing the value and impact for the three major sets of external stakeholders (people/patients, funders, and research customers) and creating a path to balanced and planned investment in biobank infrastructure and the sustainability of biobanking. Biobanking 3.0 will improve real understanding as well as perceptions of value across different stakeholders. Patients and donors will appreciate seeing how their biospecimens and data are effectively used for research. Funders will value the ability to plan efficient targeting of funding and to monitor the impact of their support. Researchers will capitalize on the ability to translate their ideas into effective knowledge. Ultimately adoption of biobanking 3.0 will impact on the sustainability in the three main dimensions relevant to biobanking: social sustainability (acceptability), operational sustainability (efficiency), and financial sustainability (accomplishment).
Collapse
|
36
|
Colledge F, Elger B, Howard HC. A Review of the Barriers to Sharing in Biobanking. Biopreserv Biobank 2013; 11:339-46. [DOI: 10.1089/bio.2013.0039] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Affiliation(s)
- Flora Colledge
- Institute of Biomedical Ethics, University of Basel, Basel, Switzerland
| | - Bernice Elger
- Institute of Biomedical Ethics, University of Basel, Basel, Switzerland
| | - Heidi C. Howard
- Department of Epidemiology and Public Health, Inserm, UMR 1027, Université de Toulouse, Toulouse, France
- Faculté de médecine Purpan, Université de Toulouse, Toulouse, France
| |
Collapse
|
37
|
Winkler EC, Ose D, Glimm H, Tanner K, von Kalle C. Personalisierte Medizin und Informed Consent: Klinische und ethische Erwägungen im Rahmen der Entwicklung einer Best Practice Leitlinie für die biobankbasierte Ganzgenomforschung in der Onkologie. Ethik Med 2013. [DOI: 10.1007/s00481-013-0273-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
38
|
Nobile H, Vermeulen E, Thys K, Bergmann MM, Borry P. Why do participants enroll in population biobank studies? A systematic literature review. Expert Rev Mol Diagn 2013; 13:35-47. [PMID: 23256702 DOI: 10.1586/erm.12.116] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Therapeutic misconception has been extensively studied and addressed within clinical trials. An equivalent in the genetic research context has been identified as diagnostic misconception. There is not much data on this phenomenon in population-based biobank studies. Since misconceptions may generate undue motives to enroll, the authors aimed at reviewing studies addressing the reasons to participate in biobank studies. The main databases were searched using relevant keywords. Studies were included if peer-reviewed, in English and describing the reasons to enroll was provided by actual and apparently healthy donors. Although the 13 studies retrieved were heterogeneous, a scheme summarizing the main aspects involved in the decision-making process was developed. Expectation of personal benefit through health-related information was found in eight studies. Three of them discussed whether this expectation could be considered a form of therapeutic misconception. The magnitude of this phenomenon is an important ethical concern and ought to be further studied.
Collapse
Affiliation(s)
- Hélène Nobile
- German Institute of Human Nutrition, Nuthetal, Germany.
| | | | | | | | | |
Collapse
|
39
|
Kamm L, Bogdanov D, Laur S, Vilo J. A new way to protect privacy in large-scale genome-wide association studies. ACTA ACUST UNITED AC 2013; 29:886-93. [PMID: 23413435 PMCID: PMC3605601 DOI: 10.1093/bioinformatics/btt066] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Motivation: Increased availability of various genotyping techniques has initiated a race for finding genetic markers that can be used in diagnostics and personalized medicine. Although many genetic risk factors are known, key causes of common diseases with complex heritage patterns are still unknown. Identification of such complex traits requires a targeted study over a large collection of data. Ideally, such studies bring together data from many biobanks. However, data aggregation on such a large scale raises many privacy issues. Results: We show how to conduct such studies without violating privacy of individual donors and without leaking the data to third parties. The presented solution has provable security guarantees. Contact:jaak.vilo@ut.ee Supplementary information:Supplementary data are available at Bioinformatics online.
Collapse
Affiliation(s)
- Liina Kamm
- Institute of Computer Science, University of Tartu, Liivi 2, Tartu 50409, Estonia
| | | | | | | |
Collapse
|
40
|
Knoppers BM, Zawati MH, Kirby ES. Sampling Populations of Humans Across the World: ELSI Issues. Annu Rev Genomics Hum Genet 2012; 13:395-413. [DOI: 10.1146/annurev-genom-090711-163834] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Bartha Maria Knoppers
- Centre of Genomics and Policy, McGill University and Genome Quebec Innovation Centre, Montreal, Quebec H3A 1A4, Canada; , ,
| | - Ma'n H. Zawati
- Centre of Genomics and Policy, McGill University and Genome Quebec Innovation Centre, Montreal, Quebec H3A 1A4, Canada; , ,
| | - Emily S. Kirby
- Centre of Genomics and Policy, McGill University and Genome Quebec Innovation Centre, Montreal, Quebec H3A 1A4, Canada; , ,
| |
Collapse
|
41
|
Norlin L, Fransson MN, Eriksson M, Merino-Martinez R, Anderberg M, Kurtovic S, Litton JE. A Minimum Data Set for Sharing Biobank Samples, Information, and Data: MIABIS. Biopreserv Biobank 2012; 10:343-8. [PMID: 24849882 DOI: 10.1089/bio.2012.0003] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Loreana Norlin
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Martin N. Fransson
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Mikael Eriksson
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Roxana Merino-Martinez
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Maria Anderberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Sanela Kurtovic
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Jan-Eric Litton
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
42
|
Herpel E, Koleganova N, Schreiber B, Walter B, Kalle CV, Schirmacher P. Structural requirements of research tissue banks derived from standardized project surveillance. Virchows Arch 2012; 461:79-86. [DOI: 10.1007/s00428-012-1258-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2012] [Revised: 04/17/2012] [Accepted: 05/21/2012] [Indexed: 10/27/2022]
|
43
|
Isasi R, Knoppers BM. From banking to international governance: fostering innovation in stem cell research. Stem Cells Int 2011; 2011:498132. [PMID: 21904557 PMCID: PMC3167189 DOI: 10.4061/2011/498132] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2011] [Accepted: 06/07/2011] [Indexed: 11/30/2022] Open
Abstract
Stem cell banks are increasingly recognized as an essential resource of biological materials for both basic and translational stem cell research. By providing transnational access to quality controlled and ethically sourced stem cell lines, stem cell banks seek to foster international collaboration and innovation. However, given that national stem cell banks operate under different policy, regulatory and commercial frameworks, the transnational sharing of stem cell materials and data can be complicating. This paper will provide an overview of the most pressing challenges regarding the governance of stem cell banks, and the difficulties in designing regulatory and commercial frameworks that foster stem cell research. Moreover, the paper will shed light on the numerous international initiatives that have arisen to help harmonize and standardize stem cell banking and research processes to overcome such challenges.
Collapse
Affiliation(s)
- Rosario Isasi
- Centre of Genomics and Policy, McGill University, Montreal, QC, Canada H3A 1A1
| | | |
Collapse
|
44
|
Siontis GC, Ioannidis JP. Risk factors and interventions with statistically significant tiny effects. Int J Epidemiol 2011; 40:1292-307. [DOI: 10.1093/ije/dyr099] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
|
45
|
Panzarasa S, Quaglini S, Ferrari R, Stefanelli M, Foli A, Palladini G, Russo P, Lavatelli F. A workflow management system for the biological samples exchange within the amyloidosis network. Amyloid 2011; 18 Suppl 1:233-5. [PMID: 21838500 DOI: 10.3109/13506129.2011.574354088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
46
|
Diaferia GR, Biunno I, DeBlasio P. Comprehensive Outsourcing Biobanking Facility to Serve the International Research Community. Biopreserv Biobank 2011; 9:191-4. [DOI: 10.1089/bio.2011.0002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | - Ida Biunno
- Integrated Systems Engineering s.r.l., Milan, Italy
- IRGB-CNR, Milano, Italy
| | - Pasquale DeBlasio
- Integrated Systems Engineering s.r.l., Milan, Italy
- BioRep s.r.l., Milan, Italy
| |
Collapse
|
47
|
|
48
|
Kohane IS. Using electronic health records to drive discovery in disease genomics. Nat Rev Genet 2011; 12:417-28. [PMID: 21587298 DOI: 10.1038/nrg2999] [Citation(s) in RCA: 237] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
If genomic studies are to be a clinically relevant and timely reflection of the relationship between genetics and health status--whether for common or rare variants--cost-effective ways must be found to measure both the genetic variation and the phenotypic characteristics of large populations, including the comprehensive and up-to-date record of their medical treatment. The adoption of electronic health records, used by clinicians to document clinical care, is becoming widespread and recent studies demonstrate that they can be effectively employed for genetic studies using the informational and biological 'by-products' of health-care delivery while maintaining patient privacy.
Collapse
Affiliation(s)
- Isaac S Kohane
- Harvard Medical School, 10 Shattuck Street, Boston, Massachusetts 02115, USA.
| |
Collapse
|
49
|
Elger BS, Biller-Andorno N. Biobanks and Research: Scientific Potential and Regulatory Challenge. THE INTERNATIONAL LIBRARY OF ETHICS, LAW AND TECHNOLOGY 2011. [DOI: 10.1007/978-94-007-1673-5_3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
|
50
|
Quality management and accreditation of research tissue banks: experience of the National Center for Tumor Diseases (NCT) Heidelberg. Virchows Arch 2010; 457:741-7. [PMID: 20978804 DOI: 10.1007/s00428-010-0998-1] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2010] [Revised: 10/06/2010] [Accepted: 10/08/2010] [Indexed: 11/27/2022]
Abstract
Tissue banks are key resource and technology platforms in biomedical research that address the molecular pathogenesis of diseases as well as disease prevention, diagnosis, and treatment. Due to the central role of tissue banks in standardized collection, storage, and distribution of human tissues and their derivatives, quality management and its external assessment is becoming increasingly relevant for the maintenance, acceptance, and funding of tissue banks. Little experience exists regarding formalized external evaluation of tissue banks, especially regarding certification and accreditation. Based on the accreditation of the National Center of Tumor Diseases (NCT) tissue bank in Heidelberg (Germany), criteria, requirements, processes, and implications were compiled and evaluated. Accreditation formally approved professional competence and performance of the tissue bank in all steps involved in tissue collection, storage, handling as well as macroscopic and histologic examination and final (exit) examination of the tissue and transfer supervised by board-certified competent histopathologists. Thereby, accreditation provides a comprehensive measure to evaluate and document the quality standard of tissue research banks and may play a significant role in the future assessment of tissue banks. Furthermore, accreditation may support harmonization and standardization of tissue banking for biomedical research purposes.
Collapse
|